NASDAQ:RVNC Revance Therapeutics (RVNC) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free RVNC Stock Alerts $4.29 +0.02 (+0.47%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$4.25▼$4.4850-Day Range$3.29▼$6.9852-Week Range$3.21▼$36.70Volume1.46 million shsAverage Volume1.79 million shsMarket Capitalization$447.09 millionP/E RatioN/ADividend YieldN/APrice Target$13.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Revance Therapeutics alerts: Email Address Revance Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside220.5% Upside$13.75 Price TargetShort InterestHealthy11.16% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.22Based on 8 Articles This WeekInsider TradingSelling Shares$143,642 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.17) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.23 out of 5 starsMedical Sector224th out of 915 stocksPharmaceutical Preparations Industry92nd out of 426 stocks 3.3 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRevance Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Revance Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.16% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Revance Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 2.3 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Revance Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for RVNC on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat Follows5 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,642.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions97.70% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revance Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($2.17) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> About Revance Therapeutics Stock (NASDAQ:RVNC)Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More RVNC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVNC Stock News HeadlinesMay 9, 2024 | msn.comRVNC Stock Earnings: Revance Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | msn.comRevance Therapeutics GAAP EPS of -$0.58, revenue of $51.94MMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 9, 2024 | businesswire.comRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateMay 9, 2024 | businesswire.comRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaMay 8, 2024 | markets.businessinsider.comRevance Therapeutics is about to announce earnings — here's what Wall Street expectsMay 8, 2024 | americanbankingnews.comRevance Therapeutics (RVNC) Scheduled to Post Earnings on ThursdayMay 2, 2024 | businesswire.comRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024May 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 2, 2024 | money.usnews.comRevance Therapeutics IncApril 12, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the companyApril 12, 2024 | businesswire.comRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingMarch 27, 2024 | finance.yahoo.comRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 16, 2024 | finance.yahoo.comRVNC Apr 2024 5.000 putMarch 11, 2024 | msn.comRevance stock rises after CEO discloses share purchaseMarch 4, 2024 | markets.businessinsider.comRevance Prices Offering Of 16 Mln Shares At $6.25/Share; Stock DropsMarch 4, 2024 | marketwatch.comRevance Therapeutics Shares Slide After Public OfferingMarch 4, 2024 | markets.businessinsider.comRevance Proposes Public Offering Of $100 Mln Of Shares; Stock Down Over 8% In Pre-marketMarch 4, 2024 | msn.comRevance Therapeutics down 7%, prices $100M share offeringMarch 4, 2024 | finance.yahoo.comRevance Announces Pricing of $100.0 Million Public Offering of Common StockMarch 4, 2024 | businesswire.comRevance Announces Proposed Public Offering of Common StockMarch 2, 2024 | finance.yahoo.comUS$16.33: That's What Analysts Think Revance Therapeutics, Inc. (NASDAQ:RVNC) Is Worth After Its Latest ResultsMarch 2, 2024 | finance.yahoo.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comRevance Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 29, 2024 | seekingalpha.comRevance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges RemainFebruary 29, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)February 29, 2024 | finance.yahoo.comQ4 2023 Revance Therapeutics Inc Earnings CallSee More Headlines Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$13.75 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+220.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-323,990,000.00 Net Margins-138.43% Pretax Margin-138.30% Return on EquityN/A Return on Assets-45.78% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.29 Sales & Book Value Annual Sales$234.04 million Price / Sales1.91 Cash FlowN/A Price / Cash FlowN/A Book Value($1.73) per share Price / Book-2.48Miscellaneous Outstanding Shares104,216,000Free Float100,568,000Market Cap$447.09 million OptionableOptionable Beta1.16 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Mark J. Foley (Age 59)CEO & Director Comp: $1.26MMr. Tobin C. Schilke (Age 49)CFO & Principal Accounting Officer Comp: $731.58kMr. Dwight O. Moxie (Age 48)Chief Legal Officer & General Counsel Comp: $713.82kJessica SerraHead of Investor Relations & ESGMs. Jeanie D. HerbertSenior Director of Investor Relations & Corporate CommunicationsMs. Taryn ConwayVice President of MarketingMs. Amie KrauseChief People OfficerDr. Conor GallagherHead of Medical Affairs & AestheticsDr. David A. Hollander M.B.A. (Age 49)M.D., Chief Medical Officer of Global Therapeutics Franchise Lead Ms. Erica Jordan (Age 47)Chief Commercial Officer More ExecutivesKey CompetitorsAcelyrinNASDAQ:SLRNPepGenNASDAQ:PEPGTheravance BiopharmaNASDAQ:TBPHEsperion TherapeuticsNASDAQ:ESPREntrada TherapeuticsNASDAQ:TRDAView All CompetitorsInsiders & InstitutionsBlair William & Co. ILBought 11,318 shares on 5/9/2024Ownership: 0.316%Inspire Investing LLCBought 29,645 shares on 5/8/2024Ownership: 0.070%Swiss National BankBought 30,000 shares on 5/7/2024Ownership: 0.187%NorthRock Partners LLCBought 30,708 shares on 5/7/2024Ownership: 0.029%Clarity Capital Partners LLCBought 12,082 shares on 5/3/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions RVNC Stock Analysis - Frequently Asked Questions Should I buy or sell Revance Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks. What is Revance Therapeutics' stock price target for 2024? 8 equities research analysts have issued 1 year price targets for Revance Therapeutics' shares. Their RVNC share price targets range from $9.00 to $20.00. On average, they predict the company's share price to reach $13.75 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts. How have RVNC shares performed in 2024? Revance Therapeutics' stock was trading at $8.79 at the beginning of the year. Since then, RVNC shares have decreased by 51.2% and is now trading at $4.29. View the best growth stocks for 2024 here. Are investors shorting Revance Therapeutics? Revance Therapeutics saw a drop in short interest in April. As of April 15th, there was short interest totaling 11,630,000 shares, a drop of 14.2% from the March 31st total of 13,550,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the short-interest ratio is currently 6.5 days. View Revance Therapeutics' Short Interest. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.17. The biopharmaceutical company earned $69.80 million during the quarter, compared to the consensus estimate of $64.02 million. What ETFs hold Revance Therapeutics' stock? ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO). Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.72%), Blair William & Co. IL (0.32%), Essex Investment Management Co. LLC (0.21%), BNP Paribas Financial Markets (0.20%), Swiss National Bank (0.19%) and Commonwealth Equity Services LLC (0.10%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Erica Jordan, Mark J Foley and Tobin Schilke. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVNC) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
